53872-60-9

Basic information

• Product Name: (+)-(3AR,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-[(1E,3R)-3-HYDROXY-4-(3-TRIFLUOROMETHYL)PHENOXY-1-BUTENYL]-2H-CYCLOPENTA[B]FURAN-2-ONE
• Synonyms: Travoprost Epoxide;(3aR,4R,5R,6aS)-5-Hydroxy-4-((R,E)-3-hydroxy-4-(3-(trifluoroMethyl)phenoxy)but-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one;Fluprostenone Lactone Diol;Anti-TERT antibody produced in goat;EST2;TCS1;TRT;Anti-Telomerase antibody produced in rabbit
• CAS NO: 53872-60-9
• Molecular Formula: C₁₈H₁₉F₃O₅
• Molecular Weight: 372.34
• Mol File: 53872-60-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 520.599 °C at 760 mmHg
• Flash Point: 268.649 °C
• Appearance: /
• Density: 1.434 g/cm³
• Refractive Index: 1.583
• Storage Temp.: -20°C
• PKA: 13.34±0.20(Predicted)
• CAS DataBase Reference: (+)-(3AR,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-[(1E,3R)-3-HYDROXY-4-(3-TRIFLUOROMETHYL)PHENOXY-1-BUTENYL]-2H-CYCLOPENTA[B]FURAN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-(3AR,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-[(1E,3R)-3-HYDROXY-4-(3-TRIFLUOROMETHYL)PHENOXY-1-BUTENYL]-2H-CYCLOPENTA[B]FURAN-2-ONE(53872-60-9)
• EPA Substance Registry System: (+)-(3AR,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-[(1E,3R)-3-HYDROXY-4-(3-TRIFLUOROMETHYL)PHENOXY-1-BUTENYL]-2H-CYCLOPENTA[B]FURAN-2-ONE(53872-60-9)

Safety Data

• Hazardous Substances Data: 53872-60-9(Hazardous Substances Data)

Usage

Uses

(3aR,?4R,?5R,?6aS)?-Hexahydro-?5-?hydroxy-?4-?[(1E,?3R)?-?3-?hydroxy-?4-?[3-?(trifluoromethyl)?phenoxy]?-?1-?buten-?1-?yl]?-?2H-?cyclopenta[b]?furan-?2-?one is involved in the preparation of prostaglandin derivatives.

InChI:InChI=1/C18H19F3O5/c19-18(20,21)10-2-1-3-12(6-10)25-9-11(22)4-5-13-14-7-17(24)26-16(14)8-15(13)23/h1-6,11,13-16,22-23H,7-9H2/b5-4+/t11-,13-,14-,15-,16+/m1/s1

Upstream product

• 114488-91-4 [1,1'-biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2-oxo-2H-cyclopenta[b]furan-5-yl ester 
• 54094-19-8 dimethyl [3-(3-(trifluoromethyl)phenoxy)-2-oxopropyl]phosphonate 
• 54142-64-2 [1,1'-biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-5-yl ester 
• 38754-71-1 (3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 
• 98-17-9 3-Trifluoromethylphenol 
• 588-26-1 methyl 2-[3-(trifluoromethyl)phenoxy]acetate 
• 31752-99-5 (-)-Corey lactone 5-(4-phenylbenzoate) 
• 1056147-98-8 (3aR,4R,5R,6aS)-4-((E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)-2oxohexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 

Downstream Products

• 1240483-24-2 (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((R,E)-3-((tert-butyldimethylsilyl)oxy)-4-(3-(trifluoromethyl)-phenoxy)but-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 1300093-02-0 (3aR,4R,5R,6aS)-5-((2-methoxyethoxy)methoxy)-4-((R,E)-3-((2-methoxyethoxy)methoxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 1300093-03-1 (3aR,4R,5R,6aS)-5-((2-methoxyethoxy)methoxy)-4-((R,E)-3-((2-methoxyethoxy)methoxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-ol 
• 1300093-04-2 (Z)-7-((1R,2R,3R,5S)-5-hydroxy-3-((2-methoxyethoxy)methoxy)-2-((R,E)-3-((2-methoxyethoxy)methoxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid 
• 1300093-06-4 (Z)-isopropyl 7-((1R,2R,3R,5S)-5-hydroxy-3-((2-methoxyethoxy)methoxy)-2-((R,E)-3-((2-methoxyethoxy)methoxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoate 
• 340181-93-3 travoprost 
• 1204185-88-5 (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-2,5-diol 
• 79124-64-4 N-(methanesulfonyl)-16--ω-tetranor-PGE₂-carboxamide 
• 208252-64-6 (3aR,4R,5R,6aS)-5-((tetrahydro-2H-pyran-2-yl)oxy)-4-((3R,E)-3-((tetrahydro-2H-pyran-2-yl)oxy)-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-ol 
• 208180-17-0 (3aR,4R,5R,6aS)-5-((tetrahydro-2H-pyran-2-yl)oxy)-4-((3R,E)-3-((tetrahydro-2H-pyran-2-yl)oxy)-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one 

Relevant articles and documents

Novel method for preparing Prostaglandin derivatives

Provided is a novel method for preparing prostaglandin derivatives. The method is suitable for mass production by effectively manufacturing prostaglandin derivatives with high yield. The method comprises the following steps: (S-1) adding a first reducing agent to a prostaglandin intermediate compound represented by chemical formula II and manufacturing a compound represented by chemical formula III; (S-2) manufacturing a compound represented by chemical formula IV from the compound represented by chemical formula III in the presence of a base; (S-3) adding a second reducing agent to the compound represented by chemical formula IV and manufacturing a compound represented by chemical formula V; and (S-4) performing Wittig reaction of the compound represented by chemical formula V and a compound represented by chemical formula VI, and manufacturing a compound represented by chemical formula I.COPYRIGHT KIPO 2017

A NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF

This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and (CH2)nOR2 wherein n is from 1 to 3 and R2 represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and R1 is selected from OR3 and NHR3 wherein R3 is C1-C6 alkyl, H; and dashed lines represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

Processes and intermediates for the preparations of prostaglandins

The present invention provides novel processes for the preparation of a cyclopentanone of Formula II and a lactone of Formula I, which are useful in the production of prostaglandins: wherein Z, R2, R3, X1, X2, and are as defined in the specification. The invention also provides novel enantiomerically enriched compounds.